Compare Heron Therapeutics Inc (HRTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs WD 40 Company — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: WD 40 Company is far larger — about 35.2× Heron Therapeutics Inc's market cap, and WD 40 Company pays a 1.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WDFC | |
|---|---|---|
Market Cap | $91.46M | $3.22B |
Sector | Health | Technology |
52-Week High | $1.96 | $264.91 |
52-Week Low | $0.39 | $187.52 |
Enterprise Value | $189.36M | $3.27B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
WDFC trades at $239.59, down 2.92% today, with a bullish technical signal supported by moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations at $2.33 EPS versus $1.58 expected, driven by strong sales growth. The company maintains solid profitability with a 13.22% net income margin and positive operating cash flow of $87.93 million in 2025, though 2026 projections show slight margin compression.
The outlook is mixed: strong brand moat and consistent cash flow support dividends, but high valuation multiples (P/E 37.5) and analyst caution (71% hold rating) limit near-term upside. Risks include input cost pressures and competitive maintenance markets. Institutional sentiment leans neutral despite recent earnings strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
